Previous Close | 2.7600 |
Open | 2.8100 |
Bid | 3.0200 x 1300 |
Ask | 3.1000 x 1000 |
Day's Range | 2.5900 - 3.0400 |
52 Week Range | 1.4600 - 9.5500 |
Volume | 1,668,023 |
Avg. Volume | 560,200 |
Market Cap | 153.463M |
Beta (3Y Monthly) | 2.14 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5900 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.20 |
LOS ANGELES, CA / ACCESSWIRE / December 6, 2019 / The Schall Law Firm ,a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abeona Therapeutics Inc. ("Abeona" ...
Pomerantz LLP announces that a class action lawsuit has been filed against Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and docketed under 19-cv-10181, is on behalf of a class consisting of investors who purchased or otherwise acquired Abeona securities between May 31, 2018 and September 23, 2019, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.
New York, New York--(Newsfile Corp. - December 6, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abeona Therapeutics Inc. (NASDAQ: ABEO) ("Abeona" or the "Company") of the December 31, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoIf you invested in Abeona stock or options between May 31, 2018 ...
NEW YORK, Dec. 05, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abeona Therapeutics Inc. (NASDAQ: ABEO) between May 31,.
New York, New York--(Newsfile Corp. - December 5, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abeona Therapeutics Inc. (NASDAQ: ABEO) ("Abeona" or the "Company") of the December 31, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoIf you invested in Abeona stock or options between May 31, 2018 ...
NEW YORK, NY / ACCESSWIRE / December 4, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Abeona Therapeutics Inc. ("Abeona" or the "Company") (ABEO) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and docketed under 19-cv-10181, is on behalf of a class consisting of investors who purchased or otherwise acquired Abeona securities between May 31, 2018 and September 23, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Abeona Therapeutics, Inc. (ABEO), AZZ, Inc. (AZZ), Under Armour, Inc. (NYSE: UA, UAA), and UP Fintech Holding Limited (TIGR). From preliminary clinical data and expert input, the Company expected EB-101 to be a potential treatment choice for most wounds, and believes it is currently the only product candidate being evaluated as a treatment for larger wounds. On September 23, 2019, Abeona issued a press release announcing receipt of a clinical hold letter from the FDA, “clarifying that the FDA will not provide approval for the Company to begin its planned Phase 3 clinical trial for EB-101 [a/k/a, the VITAL Study] until it submits to the FDA additional data points on transport stability of EB-101 to clinical sites” (the “September 2019 Press Release”).
New York, New York--(Newsfile Corp. - December 4, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abeona Therapeutics Inc. (NASDAQ: ABEO) ("Abeona" or the "Company") of the December 31, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoIf you invested in Abeona stock or options between May 31, ...
Q3 2019 Abeona Therapeutics Inc Earnings Call
LOS ANGELES, CA / ACCESSWIRE / December 2, 2019 / The Schall Law Firm ,a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abeona Therapeutics Inc. ("Abeona" ...
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.
Pawar Law Group announces that a class action lawsuit on behalf of shareholders who purchased shares of Abeona Therapeutics Inc. (ABEO) from May 31, 2018 through September 23, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Abeona Therapeutics Inc. investors under the federal securities laws. A class action lawsuit has already been filed.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sealed Air Corporation (SEE), Abeona Therapeutics, Inc. (ABEO), AZZ, Inc. (AZZ), and Under Armour, Inc. (NYSE: UA, UAA). On November 5, 2014 Sealed Air filed its quarterly report on Form 10-Q for the quarter ended September 30, 2014, which was signed by defendant Stiehl and contained signed certifications by defendants Peribere and Lowe stating that the statements contained therein were accurate and not materially misleading. The Form 10-Q stated that Sealed Air had achieved $59.3 million in net earnings for the quarter.
NEW YORK, Nov. 25, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abeona Therapeutics Inc. (NASDAQ: ABEO) between May 31,.
NEW YORK, NY / ACCESSWIRE / November 25, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can ...